PBE - Invesco Biotechnology & Genome ETF
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value.
As of May 15, 2026: spot at $81.02, ATM IV 24.0%, net GEX $2.2K.
- Sector
- Financial Services
- Industry
- Asset Management
- Market Cap
- $247.8M
- Beta
- 0.81
- 52-Week Range
- 59.75-85.73
- Dividend Yield
- $0.87
- IPO Date
- Jun 23, 2005
- Exchange
- AMEX
What PBE Looks Like to Options Traders Today
IV rank of 31.8% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($2.2K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.008) is roughly flat across the wings.
What This Page Covers
The PBE overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure.
Frequently asked PBE overview questions
- What is PBE?
- PBE is the ticker symbol for Invesco Biotechnology & Genome ETF, an listed exchange-traded fund. The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. Listed on AMEX. PBE is the ETF ticker shown on this page; ETF traders use the fund for diversified exposure to its underlying basket, for sector and factor rotation, and for hedging or replication strategies via the listed options chain.
- What does the PBE options snapshot look like today?
- As of May 15, 2026, the PBE options snapshot shows spot at $81.02, ATM IV 24.0%, IV rank 31.8%, net GEX $2.2K, expected move 6.88%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are PBE's key statistics?
- Invesco Biotechnology & Genome ETF (PBE) carries a market capitalization of $247.8M, 52-week range of 59.75-85.73. Full holdings disclosure, expense ratio, and tracking-error history live on the per-ticker fundamentals page or the sponsor's site; daily NAV and premium/discount-to-NAV are accessible from the same view. These structural inputs frame how the ETF options market prices implied volatility relative to its constituents.
- What sector or industry does PBE belong to?
- Invesco Biotechnology & Genome ETF operates in the Financial Services sector, in the Asset Management industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare PBE's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the PBE data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Fund-level fields (sponsor, expense ratio, holdings concentration where available) refresh from the vendor feed nightly. ETF-specific filings (N-CSR, N-PX, N-CEN) update on the SEC EDGAR cadence. FINRA microstructure data refreshes on the source's cadence; for ETFs the off-exchange volume signal is dominated by authorized-participant creation and redemption rather than directional flow.